162,795 Shares in Drugs Made In America Acquisition Corp. $DMAA Purchased by Sona Asset Management US LLC

Sona Asset Management US LLC acquired a new position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 162,795 shares of the company’s stock, valued at approximately $1,706,000.

Several other hedge funds have also recently bought and sold shares of the company. Sandia Investment Management LP acquired a new position in shares of Drugs Made In America Acquisition in the 3rd quarter valued at approximately $161,000. Quarry LP acquired a new stake in shares of Drugs Made In America Acquisition during the 3rd quarter worth approximately $161,000. Radcliffe Capital Management L.P. boosted its position in shares of Drugs Made In America Acquisition by 3.5% during the 4th quarter. Radcliffe Capital Management L.P. now owns 546,808 shares of the company’s stock worth $5,673,000 after acquiring an additional 18,708 shares in the last quarter. Lineage Point Capital LP bought a new position in Drugs Made In America Acquisition in the fourth quarter valued at approximately $330,000. Finally, Shaolin Capital Management LLC increased its stake in Drugs Made In America Acquisition by 50.0% in the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock valued at $1,540,000 after acquiring an additional 50,000 shares during the last quarter.

Drugs Made In America Acquisition Trading Up 0.0%

Drugs Made In America Acquisition stock opened at $10.71 on Monday. Drugs Made In America Acquisition Corp. has a 12-month low of $10.22 and a 12-month high of $10.72. The business’s 50-day moving average price is $10.63 and its two-hundred day moving average price is $10.53.

Drugs Made In America Acquisition (NASDAQ:DMAA) last posted its earnings results on Thursday, May 14th. The company reported $0.06 EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a research note on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Drugs Made In America Acquisition has an average rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.